The diagnosis and treatment of patients with cancer requires access to imaging to ensure
accurate management decisions and optimal outcomes. Our global assessment of imaging …

The incidence of lymphoma in the United States from 2009 to 2013 was approximately 22 in
100,000 people, representing 5% of malignancies. 1 Median age at diagnosis is 63 …

Abstract In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo)
administered in combination were evaluated as initial salvage therapy in patients with …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN panel meets at …

A retrospective, international, multicenter study was undertaken to assess:(i) the prognostic
role of 'interim'positron emission tomography performed during treatment with doxorubicin …

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Purpose: The prognostic impact of total metabolic tumor volume (TMTV) measured on
pretreatment 18F-FDG PET/CT and its added value to molecular characteristics was …

Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma
(HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study …

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted
postinduction approach in patients with follicular lymphoma who responded to induction …

Abstract FDG‐PET/CT is the current state‐of‐the‐art imaging in lymphoma and plays a
central role in treatment decisions. At diagnosis, accurate staging is crucial for appropriate …